These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9097868)

  • 1. High-dose naltrexone and liver function safety.
    Marrazzi MA; Wroblewski JM; Kinzie J; Luby ED
    Am J Addict; 1997; 6(1):21-9. PubMed ID: 9097868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa.
    Marrazzi MA; Bacon JP; Kinzie J; Luby ED
    Int Clin Psychopharmacol; 1995 Sep; 10(3):163-72. PubMed ID: 8675969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.
    Younger J; Noor N; McCue R; Mackey S
    Arthritis Rheum; 2013 Feb; 65(2):529-38. PubMed ID: 23359310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatients.
    Kim SW; Grant JE; Yoon G; Williams KA; Remmel RP
    Clin Neuropharmacol; 2006; 29(2):77-9. PubMed ID: 16614539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage.
    Pfohl DN; Allen JI; Atkinson RL; Knopman DS; Malcolm RJ; Mitchell JE; Morley JE
    NIDA Res Monogr; 1986; 67():66-72. PubMed ID: 3092099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of naltrexone on self-injurious behavior.
    Sandman CA; Hetrick W; Taylor DV; Marion SD; Touchette P; Barron JL; Martinezzi V; Steinberg RM; Crinella FM
    Am J Ment Retard; 2000 Mar; 105(2):103-17. PubMed ID: 10755174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naltrexone as a treatment for repetitive self-injurious behaviour:an open-label trial.
    Roth AS; Ostroff RB; Hoffman RE
    J Clin Psychiatry; 1996 Jun; 57(6):233-7. PubMed ID: 8666558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Injectable extended-release naltrexone for opioid dependence: an open label study of long-term safety and efficacy].
    Krupitsky EM; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Blokhina EA; Silverman BL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):49-56. PubMed ID: 25591636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opiate antagonists in children and adolescents.
    Chabane N; Leboyer M; Mouren-Simeoni MC
    Eur Child Adolesc Psychiatry; 2000; 9 Suppl 1():I44-50. PubMed ID: 11140779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking.
    Krishnan-Sarin S; Krystal JH; Shi J; Pittman B; O'Malley SS
    Biol Psychiatry; 2007 Sep; 62(6):694-7. PubMed ID: 17336941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in transaminases over the course of a 12-week, double-blind nalmefene trial in a 38-year-old female subject.
    Salvato FR; Mason BJ
    Alcohol Clin Exp Res; 1994 Oct; 18(5):1187-9. PubMed ID: 7847604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultra-low dose oral naltrexone decreases side effects and potentiates the effect of methadone.
    Cruciani RA; Lussier D; Miller-Saultz D; Arbuck DM
    J Pain Symptom Manage; 2003 Jun; 25(6):491-4. PubMed ID: 12782427
    [No Abstract]   [Full Text] [Related]  

  • 13. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials.
    O'Malley SS; Rounsaville BJ; Farren C; Namkoong K; Wu R; Robinson J; O'Connor PG
    Arch Intern Med; 2003 Jul; 163(14):1695-704. PubMed ID: 12885685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects.
    Johnson BA; O'Malley SS; Ciraulo DA; Roache JD; Chambers RA; Sarid-Segal O; Couper D
    J Clin Psychopharmacol; 2003 Jun; 23(3):281-93. PubMed ID: 12826990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence.
    Johnson BA; Ait-Daoud N; Prihoda TJ
    Alcohol Clin Exp Res; 2000 May; 24(5):737-42. PubMed ID: 10832917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial Findings of an Open-Label Trial of Low-Dose Naltrexone for Symptomatic Mesenteric Panniculitis.
    Roginsky G; Alexoff A; Ehrenpreis ED
    J Clin Gastroenterol; 2015 Oct; 49(9):794-5. PubMed ID: 26280708
    [No Abstract]   [Full Text] [Related]  

  • 17. Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects.
    Hay JL; La Vincente SF; Somogyi AA; Chapleo CB; White JM
    Eur J Pain; 2011 Mar; 15(3):293-8. PubMed ID: 20728384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Limited role of naltrexone in the treatment of opiate addiction].
    van Brussel GH
    Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1452-6. PubMed ID: 11503313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of hepatotoxicity with naltrexone treatment.
    Sax DS; Kornetsky C; Kim A
    J Clin Pharmacol; 1994 Sep; 34(9):898-901. PubMed ID: 7983232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in outpatients with normal weight bulimia.
    Mitchell JE; Christenson G; Jennings J; Huber M; Thomas B; Pomeroy C; Morley J
    J Clin Psychopharmacol; 1989 Apr; 9(2):94-7. PubMed ID: 2656781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.